Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases

被引：6
|
作者：
Jiang, Tao [1 ,2 ]
Xu, Xiaobo [2 ]
Chen, Xiaojuan [3 ]
Ding, Ning [2 ]
Hu, Qin [4 ]
Zhou, Caicun [1 ]
Hu, Jie [2 ]
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Dept Pulm Med, Shanghai Resp Res Inst, 180 Fenglin Rd, Shanghai 200032, Peoples R China
[3] Wenzhou Med Univ, Dept Gastroenterol, Wenzhou Clin Inst 3, Wenzhou Peoples Hosp, Wenzhou, Peoples R China
[4] Fudan Univ, Shanghai Resp Res Inst, Zhongshan Hosp, Dept Pathol, Shanghai, Peoples R China
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2020年 / 9卷 / 06期
基金：
中国国家自然科学基金;
关键词：
CELL LUNG-CANCER; ERLOTINIB; SURVIVAL;
D O I：
10.21037/tlcr-20-984
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2514 / 2517
页数：4
相关论文
共 50 条
  • [1] Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
    Mei-Mei Zheng
    Yang-Si Li
    Hai-Yan Tu
    Hao Sun
    Kai Yin
    Ben-Yuan Jiang
    Jin-Ji Yang
    Xu-Chao Zhang
    Qing Zhou
    Chong-Rui Xu
    Zhen Wang
    Hua-Jun Chen
    De-Xiang Zhou
    Yi-Long Wu
    BMC Medicine, 20
  • [2] Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
    Zheng, Mei-Mei
    Li, Yang-Si
    Tu, Hai-Yan
    Sun, Hao
    Yin, Kai
    Jiang, Ben-Yuan
    Yang, Jin-Ji
    Zhang, Xu-Chao
    Zhou, Qing
    Xu, Chong-Rui
    Wang, Zhen
    Chen, Hua-Jun
    Zhou, De-Xiang
    Wu, Yi-Long
    BMC MEDICINE, 2022, 20 (01)
  • [3] Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC
    Zheng, Mei-Mei
    Li, Yang-Si
    Tu, Hai-Yan
    Jiang, Ben-Yuan
    Yang, Jin-Ji
    Zhou, Qing
    Xu, Chong-Rui
    Yang, Xiao-Rong
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (02) : 250 - 258
  • [4] A Retrospective Study of Aumolertinib in Combination with Bevacizumab for EGFR-mutated NSCLC with the Presence of Leptomeningeal Metastasis
    Fang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S422 - S422
  • [5] Osimertinib in Resected EGFR-Mutated NSCLC
    Tsuboi, Masahiro
    Herbst, Roy S.
    Wu, Yi-Long
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (14): : 1341 - 1342
  • [6] Osimertinib with Chemotherapy in EGFR-Mutated NSCLC
    van Doorn-Khosrovani, Sahar Barjesteh van Waalwijk
    Badrising, Sushil K.
    Burgers, Sjaak
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (05): : 478 - 479
  • [7] Osimertinib in EGFR-Mutated Advanced NSCLC
    Yan, Kelvin
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (19): : 1863 - 1863
  • [8] Osimertinib in patients with EGFR-mutated NSCLC and leptomeningeal or brain metastases: Results of the IFCT-1804 ORBITAL trial
    Planchard, D.
    Toffart, A. C.
    Flandin, A-C. Madroszyk
    Wislez, M.
    Martinez, S.
    Monnet, I.
    Hiret, S.
    Gounant, V.
    Metivier, A-C.
    Domblides, C.
    Giroux-Leprieur, E.
    Huchot, E.
    Tomasini, P.
    Mascaux, C.
    Carmier, D.
    Langlais, A.
    Morin, F.
    Westeel, V.
    Cortot, A.
    ANNALS OF ONCOLOGY, 2023, 34
  • [9] Matched Targeted Therapy by cfDNA of CSF Beyond Leptomeningeal Metastases Progression Upon Osimertinib in EGFR-Mutated NSCLC Patients
    Zheng, M.
    Li, Y.
    Tu, H.
    Sun, H.
    Yin, K.
    Yang, J.
    Zhang, X.
    Zhou, Q.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S877 - S877
  • [10] A Retrospective Study of Aumolertinib Monotherapy or Combination Therapy Treated EGFR-mutated NSCLC Patients with Leptomeningeal Metastases
    Huang, S.
    Li, L.
    Yan, N.
    Zhang, H.
    Guo, S.
    Guo, Q.
    Geng, D.
    Li, X.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S433 - S433
12345